Navigation Links
UCLA study assesses cost-effectiveness of Hepatitis B drugs

Center for the Study of Digestive Healthcare Quality and Outcomes and assistant professor of medicine, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System. "The combined treatment strategy of lamivudine and adefovir is also a very viable option. This is part of a trend that we're seeing in other areas of medicine as well ?to use "hybrid" treatments that reserve expensive yet effective drugs for specific patients who have shown no success with other treatments."

Spiegel notes that the general cost-effectiveness standard accepted by society and many insurers for treating a chronic condition like hepatitis B is roughly $50,000 or less per quality-adjusted life-year gained, which is a standard measure used in assessing the outcome of health care procedures or services.

According to Kanwal, the study showed that only two strategies fell well within this accepted standard: Interferon cost an incremental $6,337 to gain an additional quality-adjusted life-year, compared to receiving no treatment at all. Compared with interferon, the hybrid strategy of lamivudine and adefovir cost an incremental $8,446 per quality-adjusted life-year.

In comparison, treatment with adefovir alone cost over $90,000 for each quality-adjusted life-year gained for patients with the e-antigen negative hepatitis B and would not be considered cost-effective according to researchers.

The comprehensive economic model adjusted for various patient scenarios including viral resistance, development of cirrhosis and other factors affecting treatment. Health costs included physician visits, diagnostic tests and complications of chronic liver disease.

Investigators based the model on average 40-year old patients with the most common type of chronic hepatitis B -- with elevated liver enzymes but no liver cirrhosis. Investigators also took into consideration the two types of hepatitis B -- either e- antigen positive or e-antigen negative
'"/>

Source:University of California - Los Angeles


Page: 1 2 3

Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: UCLA study assesses cost effectiveness Hepatitis drugs

(Date:4/22/2014)... secret to get your child to behave at the dinner ... Cornell study published in Eating Behaviors , found that ... bite with their front teeth such as drumsticks, whole apples, ... when these foods had been cut. "They were twice ... other kids," said Brian Wansink, Professor and Director of the ...
(Date:4/22/2014)... Scientists from the Florida campus of The Scripps ... plays a critical but previously unknown role in learning ... a novel role for a protein known as RGS7, ... eLife , a publisher supported by the Howard Hughes ... Trust. , "This is a critical building block that ...
(Date:4/22/2014)... of Massachusetts Amherst and the Instituto Nacional de Pesquisas ... have discovered a new genus and species of electric ... the Amazonia State of Brazil. , Professor Cristina Cox ... Antnio Alves-Gomes of INPA, describe the new bluntnose knifefish ... of the Natural Sciences of Philadelphia . , ...
Breaking Biology News(10 mins):Biting vs. chewing 2Scientists identify critical new protein complex involved in learning and memory 2New electric fish genus and species discovered in Brazil's Rio Negro 2
... A major initiative to create alternative nesting sites for the ... help protect juvenile salmon and steelhead in the Columbia River ... nesting site at Crump Lake in southern Oregon, which was just ... more than 135 nesting pairs of Caspian terns, as well as ...
... called for Europe to invest more funds into the study ... role in the function of human cells and which are ... to Alzheimer,s. Common lipids such as cholesterol are known ... cells and tissues, but human cells contain thousands of different ...
... Belfast is appealing for help from the public in looking ... Activities such as aquaculture, shipping and recreational boating have led ... Now Queen,s is attempting to find out exactly where and how ... this it is asking for help from the public to record ...
Cached Biology News:Project succeeding to relocate Caspian terns 2Project succeeding to relocate Caspian terns 3Project succeeding to relocate Caspian terns 4Project succeeding to relocate Caspian terns 5Project succeeding to relocate Caspian terns 6Europe-wide investment in lipid research will help tackle disease, says new report 2Queen's marine biologist investigates aliens beneath the waves 2
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... 2014 EquitiesIQ, a leading informational research ... Alliqua is an emerging biomedical company acquiring, developing, manufacturing, ... market. , Free report download: http://equitiesiq.com/reports/alliqua/ , ... management team and Board, which launched the company’s new ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management ... Product Strategy. In this role, Michelle will work with current ... in the development of iLab products. Her main goal will ... to the scientific community by offering the most advanced, user-friendly, ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... new way to manipulate light a million times more efficiently ... , Using a special hollow-core photonic crystal fibre, a ... door to what could prove to be a new sub-branch ... The team, led by Dr Fetah Benabid, reports on the ...
... PARK, Ill., Nov. 16 The Committee for,Medicinal ... of the,European Medicines Agency (EMEA), granted Abbott (NYSE: ... HUMIRA(R) (adalimumab) for the treatment,of moderate to severe ... for HUMIRA. Psoriasis is a non-contagious, chronic ...
... available in German . , Many scientists ... for the production of tiny particles with defined size ... in two or three dimensions and at both the ... applications in modern technology, from diagnostic systems to the ...
Cached Biology Technology:Discovery of a new way to manipulate light a million times more efficiently 2Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 2Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 3Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 4Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 5Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 6Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 7Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 8Two-faced miniatures 2
... Stabilizer is an aqueous solution that contains ... chemicals in a PBS buffer (phosphate buffered ... product does not contain a preservative. ... activity of dried protein components in immunoassays ...
Mouse polyclonal antibody to BTG2 - BTG family, member 2...
These 96-well 0.2 ml thin-wall PCR plate caps are caps that are used to seal 96-well, 0.2 ml thin-wall PCR plates. Supplied as 300 caps....
... for assays of mouse hematopoietic progenitors from ... Suitable for the growth of mouse ... to methylcellulose at a final concentration of ... also support growth of mouse IL-3 dependent ...
Biology Products: